Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 157


Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.

Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA.

J Clin Oncol. 2018 Jun 15:JCO2018777672. doi: 10.1200/JCO.2018.77.7672. [Epub ahead of print]


A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer.

Guo NL, Dowlati A, Raese RA, Dong C, Chen G, Beer DG, Shaffer J, Singh S, Bokhary U, Liu L, Howington J, Hensing T, Qian Y.

EBioMedicine. 2018 Jun;32:102-110. doi: 10.1016/j.ebiom.2018.05.025. Epub 2018 Jun 1.


Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.

Invest New Drugs. 2018 May 21. doi: 10.1007/s10637-018-0610-0. [Epub ahead of print]


KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.

Ardeshir-Larijani F, Bhateja P, Lipka MB, Sharma N, Fu P, Dowlati A.

Clin Lung Cancer. 2018 Jul;19(4):e489-e501. doi: 10.1016/j.cllc.2018.03.005. Epub 2018 Mar 16.


Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.


The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells.

De S, Lindner DJ, Coleman CJ, Wildey G, Dowlati A, Stark GR.

Cancer Res. 2018 May 1;78(9):2396-2406. doi: 10.1158/0008-5472.CAN-17-1920. Epub 2018 Feb 13.


Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies.

Caimi PF, Cooper BW, William BM, Dowlati A, Barr PM, Fu P, Pink J, Xu Y, Lazarus HM, de Lima M, Gerson SL.

Oncotarget. 2017 Aug 9;8(45):79864-79875. doi: 10.18632/oncotarget.20094. eCollection 2017 Oct 3.


Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer.

McColl K, Wildey G, Sakre N, Lipka MB, Behtaj M, Kresak A, Chen Y, Yang M, Velcheti V, Fu P, Dowlati A.

Oncotarget. 2017 Aug 28;8(43):73745-73756. doi: 10.18632/oncotarget.20572. eCollection 2017 Sep 26.


Relationship between phase I study duration and symptom burden.

Treasure M, Daly B, Fu P, Kerpedjieva S, Dowlati A, Meropol NJ.

Support Care Cancer. 2018 Mar;26(3):731-737. doi: 10.1007/s00520-017-3879-1. Epub 2017 Oct 5.


Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.

Bhateja P, Dowlati A, Sharma N.

Invest New Drugs. 2018 Jun;36(3):435-441. doi: 10.1007/s10637-017-0515-3. Epub 2017 Oct 2.


Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.

Gerber DE, Swanson P, Lopez-Chavez A, Wong L, Dowlati A, Pennell NA, Cronier DM, Qin A, Ilaria R Jr, Cosaert J, Shahir A, Baggstrom MQ.

Lung Cancer. 2017 Sep;111:108-115. doi: 10.1016/j.lungcan.2017.07.009. Epub 2017 Jul 18.


Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer.

Kang KH, Efird JT, Sharma N, Yang M, Dowlati A, Linden P, Machtay M, Biswas T.

Future Oncol. 2017 Jul;13(16):1405-1414. doi: 10.2217/fon-2017-0045. Epub 2017 Jul 7.


[How I explore…. HLA class II by ultrastructure in toxic epidermal necrolysis].

Piérard GE, Dowlati A, Piérard-Franchimont C, Paquet P, Delvenne P.

Rev Med Liege. 2016 Jun;71(6):298-301. Review. French.


Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.

Tacastacas JD, Chan DV, Carlson S, Gerson SL, Dowlati A, Fu P, Lu K, Groft S, Rosenjack J, Honda K, McCormick TS, Cooper KD.

JAMA Dermatol. 2017 May 1;153(5):413-420. doi: 10.1001/jamadermatol.2016.5793.


Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.

Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, Massion PP, Rudin CM, Poirier JT.

Cancer Cell. 2017 Feb 13;31(2):286-299. doi: 10.1016/j.ccell.2017.01.006.


A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.

Wu B, Lewis LD, Harvey RD, Rasmussen E, Gamelin E, Sun YN, Friberg G, Koyner JL, Dowlati A, Maitland ML.

Clin Pharmacol Ther. 2017 Aug;102(2):313-320. doi: 10.1002/cpt.617. Epub 2017 Jun 9.


Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).

Augert A, Zhang Q, Bates B, Cui M, Wang X, Wildey G, Dowlati A, MacPherson D.

J Thorac Oncol. 2017 Apr;12(4):704-713. doi: 10.1016/j.jtho.2016.12.011. Epub 2016 Dec 19.


RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.

Sakre N, Wildey G, Behtaj M, Kresak A, Yang M, Fu P, Dowlati A.

Oncotarget. 2017 Jan 24;8(4):5992-6002. doi: 10.18632/oncotarget.13362.


Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine.

Oleinick NL, Biswas T, Patel R, Tao M, Patel R, Weeks L, Sharma N, Dowlati A, Gerson SL, Fu P, Zhang J, Machtay M.

Radiother Oncol. 2016 Nov;121(2):335-341. doi: 10.1016/j.radonc.2016.10.007. Epub 2016 Nov 9.


Evaluating the role of phase I expansion cohorts in oncologic drug development.

Norris RE, Behtaj M, Fu P, Dowlati A.

Invest New Drugs. 2017 Feb;35(1):108-114. doi: 10.1007/s10637-016-0394-z. Epub 2016 Oct 7. Review.


Supplemental Content

Loading ...
Support Center